Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Dr. John Fralick and Dr. Michael Fralick, Dr. John Fralick, and Dr. Michael Fralick. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr. John Fralick and Dr. Michael Fralick, Dr. John Fralick, and Dr. Michael Fralick or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Episode 144 - Rituximab for EGPA

6:31
 
Share
 

Manage episode 521440556 series 3381372
Content provided by Dr. John Fralick and Dr. Michael Fralick, Dr. John Fralick, and Dr. Michael Fralick. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr. John Fralick and Dr. Michael Fralick, Dr. John Fralick, and Dr. Michael Fralick or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Send us a text

Welcome back Rounds Table Listeners! We are back today with a solo episode with Dr. John Fralick. This week, he discusses a recently published trial comparing rituximab with conventional strategy for the induction of remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). Here we go!

  1. Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis: A Randomized Controlled Trial (0:00 – 5:40).

The Good Stuff (5:41 – 6:31):

Questions? Comments? Feedback? We’d love to hear from you! @roundstable @InternAtWork @MedicinePods

  continue reading

403 episodes

Artwork
iconShare
 
Manage episode 521440556 series 3381372
Content provided by Dr. John Fralick and Dr. Michael Fralick, Dr. John Fralick, and Dr. Michael Fralick. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr. John Fralick and Dr. Michael Fralick, Dr. John Fralick, and Dr. Michael Fralick or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Send us a text

Welcome back Rounds Table Listeners! We are back today with a solo episode with Dr. John Fralick. This week, he discusses a recently published trial comparing rituximab with conventional strategy for the induction of remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). Here we go!

  1. Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis: A Randomized Controlled Trial (0:00 – 5:40).

The Good Stuff (5:41 – 6:31):

Questions? Comments? Feedback? We’d love to hear from you! @roundstable @InternAtWork @MedicinePods

  continue reading

403 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play